CTX0294885
CTx-0294885 is a novel bisanilino pyrimidine. It has inhibitory activity towards a wild range of kinases in vitro. CTx-0294885 is capable of capturing more than half of the expressed kinome in MDA-MB-231 cells. Large-scale CTx-0294885-based affinity purification with LC−MS/MS identifies 235 protein kinases. CTx-0294885 binds additional kinases that were not identified from previous studies using other kinase capture reagents. It is further developed into a Sepharose-supported kinase capture reagent. CTx-0294885 is a new tool for analysis of kinome signaling networks. [1]
Reference:
1. Zhang L, Holmes IP, Hochgräfe F et al. Characterization of the novel broad-spectrum
kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based
kinome profiling. J Proteome Res. 2013 Jul 5;12(7):3104-16.
Physical Appearance | A solid |
Storage | Store at -20°C |
M.Wt | 437.93 |
Cas No. | 1439934-41-4 |
Formula | C22H24ClN7O |
Solubility | ≥21.9 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O |
Chemical Name | (Z)-2-((E)-(5-chloro-2-((4-(piperazin-1-yl)phenyl)amino)pyrimidin-4(3H)-ylidene)amino)-N-methylbenzimidic acid |
SDF | Download SDF |
Canonical SMILES | C/N=C(O)/C1=CC=CC=C1/N=C(N2)\C(Cl)=CN=C2NC3=CC=C(N4CCNCC4)C=C3 |
Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Kinase experiment [1]: | |
Inhibitory assays |
A panel of 10 kinases consisting of FAK, Flt3, JAK2, JAK3, CSF-1R, SRC, VEGFR3, Aurora A, LIMK1, and ROCK2 was initially used to evaluate kinase inhibition profiles. 15 μL assay reactions were performed in Greiner brand white 384-well, low-volume plates. All reactions contained assay buffer (10 mM HEPES pH 7.4, 10 mM MgCl2, 0.01% (v/v) Tween-20, 50 μM Na3VO4, 0.01% (w/v) albumin from chicken egg white, 1 mM dithiothreitol), a N-terminally biotinylated peptide substrate (concentration 111 nM), and ATP at a concentration equaling the KM (ATP) of the kinase. The compounds were added in a volume of 100 nL from an 11-point-dilution series prepared in DMSO, positive and negative control reactions receiving the same volume of DMSO without compound. The kinases were added at predetermined concentrations, generally ranging between 0.2 and 8 nM, with the enzyme being omitted from negative control reactions. The reactions were incubated for 90 min at 30 °C and stopped by adding 5 μL of Stop buffer (10 mM HEPES pH 7.4, 25 mM NaCl, 100 mM EDTA, 0.01% (v/v) Tween-20) containing streptavidin-coated donor and antiphosphotyrosine (P-Tyr-100) acceptor beads. Plates were incubated for 4–6 h before being read on a PerkinElmer EnVision plate reader in HTS Alphascreen mode. |
Cell experiment [1]: | |
Cell lines |
MDA-MB-231 Cells |
Preparation method |
The solubility of this compound in DMSO is > 21.9 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition |
1 μM |
Applications |
CTX-0294885 exhibited inhibitory activity against a broad range of kinases in vitro, and further developed it into a Sepharose-supported kinase capture reagent. Large-scale CTx-0294885-based affinity purification followed by LC-MS/MS led to the identification of 235 protein kinases from MDA-MB-231 cells, including all members of the AKT family that had not been previously detected by other broad-spectrum kinase inhibitors. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Zhang L, Holmes I P, Hochgrafe F, et al. Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling[J]. Journal of proteome research, 2013, 12(7): 3104-3116. |
Quality Control & MSDS
- View current batch:
Chemical structure
